Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma

Gynecologic Oncology

Volumn 71, Issue 1, 1998, Pages 38-45

  Kim, Young Tae ^a   Cho, Nam Hoon ^a   Park, Sang Won ^a   Kim, Jae Wook ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR;

ARTICLE; CELL HYPERPLASIA; DNA REPLICATION; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; RECEPTOR DOWN REGULATION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

EID: 0032190669     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5134     Document Type: Article

References (38)

1. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 78:1994;67-74.
2. waf1/cip1. Cancer Res. 55:1995;2910-2919.
3. waf1/cip1. J Pathol. 180:1996;122-128.
4. Hirama T, Miller C W, Wilczynski S P, Koeffler H P. p16 (CDKN2, cyclin dependent kinase-4 inhibitor, multiple tumor suppressor-1 gene is not alterred in uterine cervical carcinomas or cell lines. Mod Pathol. 9:1996;26-31.
5. waf1/cip1. Hum Pathol. 27:1997;60-66.
6. Kelley M J, Otterson G A, Kaye F J, Popexcu N C, Johnson B E, Dipaolo J A. CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. Int J Cancer. 63:1995;226-230.
7. Reznikoff C A, Yeager T R, Belair C D, Savelieva E, Puthenveettii J A, Stadler W M. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res. 56:1996;2886-2890.
8. Nakao Y, Yang X, Yokoyama M, Ferenczy A, Tang S C, Pater M M, Pater A. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Int J Cancer. 78:1997;1410-1416.
9. Yang X, Jin G, Nakao Y, Ratsmutula M, Pater M M, Pater A. Malignant transformation of HPV 16-immortalized human endocervical cells by cigarrete smoke condensate and characterization of multistage carcinogenesis. Int J Cancer. 65:1996;338-344.
10. Olshan A F, Weissler M C, Pei H, Conway K, Anderson S, Fried D B, Yarbrough W G. Alterations of the p16 gene in head and neck cancer: frequency and association with p53, PRAD-1 and HPV. Oncogene. 14:1997;811-818.
11. Serrano M, Hannon G J, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/Cdk4. Nature. 366:1993;704-707.
12. ink4. Cancer Res. 54:1994;5816-5820.
13. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I gene in esophageal squamous cell carcinoma. Cancer Res. 54:1994;3396-3397.
14. Caldas C, Hahn S A, da Costa L T, Redston M S, Schutte M, Seymour A B, Weinstein C L, Hrubam R H, Yeo C J, Kern S E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 8:1994;27-32.
15. ink4. Cancer Res. 55:1995;505-509.
16. Waga S, Hannon G J, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature. 369:1994;574-577.
17. Xiong Y, Hannon G J, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 366:1993;701-704.
18. Harper J W, Elledge S J, Keyomarsi K, Dynlacht B, Tsai L H, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell W. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 6:1995;387-400.
19. Hall M, Bates S, Peters G. Evidence for different models of action of cyclin-dependent kinase inhibitors:p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene. 11:1995;1581-1588.
20. Cho N H, Kim Y T, Kim J W. Correlation between G1 cyclins and HPV in the uterine cervix. Int J Gynecol Pathol. 6:1997;339-347.
21. Baldin V, Lukas J, Marcote M J, Pagano M, Draetta G. Cycon D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 7:1993;812-821.
22. Lukas J, Muller H, Bartkova J, Spitkovsky D, Kjerelff A A, Jansen-Deuu P, Strauss M, Bartek J. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol. 125:1994;625-638.
23. El-Deiry W S, Tokino T, Velculescu V E, Levy D B, Parsons R, Trent J M, Lin D, Mercer W E, Kinzler K W, Vogelstein B. Waf1, a potential mediator of p53 tumor suppression. Cell. 75:1993;817-825.
24. Lo K W, Huang D P, Lau K M. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res. 55:1995;2039-2043.
25. Kamb A, Gruis N, Feldhaus J, Liu Q, Harshnman K, Tavtigian S, Stockert E, Day R, Johnson B, Skolnick M. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 264:1994;436-439.
26. Nobori T, Miura K, Wu D J, Lois A, Takabayashi K, Carson D A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 368:1994;753-756.
27. Zhang S Y, Klein-Szanto A JP, Sauter E R, Shafarenko M, Mitsunaga S, Nobori T, Carson D A, Ridge J A, Goodrow T L. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinomas cell lines than in primary tumors of the head and neck. Cancer Res. 54:1994;5050-5053.
28. INK4. Proc Natl Acad Sci USA. 91:1994;11045-11049.
29. Cairns P, Mao L, Merlo A, Lee D J, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund J, Sidransky D. Rates of p16 (MTS1) mutations in primary tumor with 9p loss. Science. 265:1994;415-416.
30. Reed A L, Califano J, Cairns P, Westra W H, Jones R M, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res. 56:1996;3630-3633.
31. INK4. Cancer Res. 55:1995;6006-6011.
32. WAF1/CIP1. Mod Pathol. 10:1997;578-584.
33. Singleton T P, Strickler J G. Clinical and patholgic significance of the c-erbB-2(HER-2/neu) oncogene. Pathol Annu. 1:1992;165-190.
34. Sigemasa K, West C M, Moon S H, Parham G P, Parmley T H, Korourian S, Barker V V, O'Brien T J. p21: a monitor of p53 dysfunction in ovarian neoplasia. Int J Gynecol Cancer. 7:1997;296-303.
35. INK4. Int J Cancer. 61:1995;115-120.
36. Yeager T, Stadler W, Belair C, Puthenveettiil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res. 55:1995;493-497.
37. Sakaguchi M, Fujii Y, Hirabayashi H, Yoon H, Komoto Y, Oue T, Kusafuka T, Okada A, Matsuda H. Inverselt correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer. 65:1996;442-445.
38. Scheffner M, Werness B A, Huibregtse J M, Levine A J, Howley P M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1990;1129-1136.